Exploring the role of phosphodiesterase PDE5 inhibition in the treatment of muscular dystrophy

Drugs of the Future

Volumn 36, Issue 4, 2011, Pages 321-339

  Yasuhara, S E ^a  

^a SHRINERS HOSPITALS FOR CHILDREN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AVANAFIL; CAFFEINE; DYSTROPHIN; GLYCYRRHIZIC ACID; INDUCIBLE NITRIC OXIDE SYNTHASE; LODENAFIL; MIRODENAFIL; NITRIC OXIDE; PENTOXIFYLLINE; PHOSPHODIESTERASE V INHIBITOR; SILDENAFIL; TADALAFIL; THEOPHYLLINE; UDENAFIL; URSODEOXYCHOLIC ACID; VARDENAFIL;

DISEASE SEVERITY; DRUG EFFICACY; DRUG MECHANISM; DRUG SELECTIVITY; DRUG STRUCTURE; DUCHENNE MUSCULAR DYSTROPHY; ENZYME SPECIFICITY; ERECTILE DYSFUNCTION; GENE MUTATION; HEART INFARCTION; HUMAN; HYPOTENSION; ISCHEMIC OPTIC NEUROPATHY; MUSCLE BIOPSY; MUSCLE BLOOD FLOW; MUSCLE CONTRACTILITY; MUSCLE FORCE; MUSCULAR DYSTROPHY; MYALGIA; MYOPATHY; NONHUMAN; PULMONARY HYPERTENSION; RETINOPATHY; REVIEW;

EID: 84952982522     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2011.036.04.1579114     Document Type: Review

References (170)

1. Furchgott, R.F., Zawadzki, J.V. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980, 288(5789): 373-6. (Pubitemid 11169009)
2. Ignarro, L.J., Buga, G.M., Wood, K.S., Byrns, R.E., Chaudhuri, G. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci U S A 1987, 84(24): 9265-9.
3. Murad, F., Waldman, S., Molina, C., Bennett, B., Leitman, D. Regulation and role of guanylate cyclase-cyclic GMP in vascular relaxation. Prog Clin Biol Res 1987, 249: 65-76.
4. Palmer, R.M., Ferrige, A.G., Moncada, S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987, 327(6122): 524-6. (Pubitemid 17085822)
5. Arnold, W.P., Mittal, C.K., Katsuki, S., Murad, F. Nitric oxide activates guanylate cyclase and increasesguanosine 3′:5′-cyclic monophosphate levels in various tissue preparations. Proc Natl Acad Sci U S A 1977, 74(8): 3203-7. (Pubitemid 8180317)
6. Fiscus, R.R., Rapoport, R.M., Murad, F. Endothelium-dependent and nitrovasodilator-induced activation of cyclic GMP-dependent protein kinase in rat aorta. J Cyclic Nucleotide Protein Phosphor Res 1983-1984, 9(6): 415-25. (Pubitemid 15189974)
7. Murad, F. Cyclic guanosine monophosphate as a mediator of vasodilation. J Clin Invest 1986, 78(1): 1-5. (Pubitemid 16068173)
8. Ignarro, L.J., Harbison, R.G., Wood, K.S., Kadowitz, P.J. Activation of purified soluble guanylate cyclase by endothelium-derived relaxing factor from intrapulmonary artery and vein: stimulation by acetylcholine, bradykinin and arachidonic acid. J Pharmacol Exp Ther 1986, 237(3): 893-900. (Pubitemid 16088110)
9. Keravis, T., Lugnier, C. Cyclic nucleotide phosphodiesterases (PDE) and peptide motifs. Curr Pharm Des 2010, 16(9): 1114-25.
10. Boolell, M., Gepi-Attee, S., Gingell, J.C., Allen, M.J. Sildenafil, a novel effective oral therapy for male erectile dysfunction. Br J Urol 1996, 78(2): 257-61. (Pubitemid 27407907)
11. Daugan, A., Grondin, P., Ruault, C. et al. The discovery of tadalafil: A novel and highly selective PDE5 inhibitor. 2: 2,3,6,7,12,12a- Hexahydropyrazino[1′,2′:1,6]pyrido[3,4-b]indole-1,4-dione analogues. J Med Chem 2003, 46(21): 4533-42. (Pubitemid 37238754)
12. Daugan, A., Grondin, P., Ruault, C. et al. The discovery of tadalafil: A novel and highly selective PDE5 inhibitor. 1: 5,6,11,11a-Tetrahydro-1H- imidazo[1′,5′:1,6]pyrido[3,4-b]indole-1,3(2H)-dione analogues. J Med Chem 2003, 46(21): 4525-32. (Pubitemid 37238753)
13. Haning, H., Niewohner, U., Schenke, T., Es-Sayed, M., Schmidt, G., Lampe, T., Bischoff, E. Imidazo[5,1-f]triazin-4(3H)-ones, a new class of potent PDE 5 inhibitors. Bioorg Med Chem Lett 2002, 12(6): 865-8. (Pubitemid 34214962)
14. Neumeyer, K., Kirkpatrick, P. Tadalafil and vardenafil. Nat Rev Drug Discov 2004, 3(4): 295-6. (Pubitemid 38499752)
15. Prasad, S., Wilkinson, J., Gatzoulis, M.A. Sildenafil in primary pulmonary hypertension. (2000) N Engl J Med 2000, 343(18): 1342.
16. Abrams, D., Schulze-Neick, I., Magee, A.G. Sildenafil as a selective pulmonary vasodilator in childhood primary pulmonary hypertension. Heart 2000, 84(2): E4.
17. Weimann, J., Ullrich, R., Hromi, J., Fujino, Y., Clark, M.W., Bloch, K.D., Zapol, W.M. Sildenafil is a pulmonary vasodilator in awake lambs with acute pulmonary hypertension. Anesthesiology 2000, 92(6): 1702-12. (Pubitemid 30412491)
18. Asai, A., Sahani, N., Kaneki, M., Ouchi, Y., Martyn, J.A., Yasuhara, S.E. Primary role of functional ischemia, quantitative evidence for the two-hit mechanism, and phosphodiesterase-5 inhibitor therapy in mouse muscular dystrophy. PLoS One 2007, 2(8): e806.
19. Khairallah, M., Khairallah, R.J., Young, M.E. et al. Sildenafil and cardiomyocyte-specific cGMP signaling prevent cardiomyopathic changes associated with dystrophin deficiency.Proc Natl Acad Sci U S A 2008, 105(19): 7028-33. (Pubitemid 351754524)
20. Kobayashi, Y.M., Rader, E.P., Crawford, R.W. et al. Sarcolemma-localized nNOS is required to maintain activity after mild exercise. Nature 2008, 456(7221): 511-5. (Pubitemid 352759004)
21. Ducheme, G. Recherches sur la paralysie musculaire pseudo-hypertrophique ou paralysie myosclerosique (2e article) - Symptomatologie - Marche, duree, terminaison. Arch Med 1868, 6(1): 179-209.
22. Griesinger, W. Ueber Muskelhypertrophie. Arch Heilkunde 1865, 6: 1-13.
23. Meryon, E. On granular and fatty degeneration of hte voluntary muscles. Med Chir Trans 1852, 35: 73-85.
24. Emery, A.E. Population frequencies of inherited neuromuscular diseases- a world survey. Neuromuscul Disord 1991, 1(1): 19-29.
25. Hoffman, E.P., Kunkel, L.M. Dystrophin abnormalities in Duchenne/Becker muscular dystrophy. Neuron 1989, 2(1): 1019-29.
26. Menke, A., Jockusch, H. Decreased osmotic stability of dystrophin-less muscle cells from the mdx mouse. Nature 1991, 349(6304): 69-71. (Pubitemid 21912016)
27. Menke, A., Jockusch, H. Extent of shock-induced membrane leakage in human and mouse myotubes depends on dystrophin. J Cell Sci 1995, 108(Pt. 2): 727-33.
28. Pasternak, C., Wong, S., Elson, E.L. Mechanical function of dystrophin in muscle cells. J Cell Biol 1995, 128(3): 355-61.
29. Schotland, D.L., Bonilla, E., Van Meter, M. Duchenne dystrophy: Alteration in muscle plasma membrane structure. Science 1977, 196(4293): 1005-7. (Pubitemid 8106054)
30. Sha'afi, R.I., Rodan, S.B., Hintz, R.L., Fernandez, S.M., Rodan, G.A. Abnormalities in membrane microviscosity and ion transport in genetic muscular dystrophy. Nature 1975, 254(5500): 525-6.
31. Sander, M., Chavoshan, B., Harris, S.A., Iannaccone, S.T., Stull, J.T., Thomas, G.D., Victor, R.G. Functional muscle ischemia in neuronal nitric oxide synthase-deficient skeletal muscle of children with Duchenne muscular dystrophy. Proc Natl Acad Sci U S A 2000, 97(25): 13818-23.
32. Thomas, G.D., Sander, M., Lau, K.S., Huang, P.L., Stull, J.T., Victor, R.G. Impaired metabolic modulation of alpha-adrenergic vasoconstriction in dystrophin-deficient skeletal muscle. Proc Natl Acad Sci U S A 1998, 95(25): 15090-5. (Pubitemid 29003761)
33. Wang, X., Weisleder, N., Collet, C. et al. Uncontrolled calcium sparks act as a dystrophic signal for mammalian skeletal muscle. Nat Cell Biol 2005, 7(5): 525-30. (Pubitemid 40637413)
34. Whitehead, N.P., Yeung, E.W., Allen, D.G. Muscle damage in mdx (dystrophic) mice: Role of calcium and reactive oxygen species. Clin Exp Pharmacol Physiol 2006, 33(7): 657-62. (Pubitemid 43894030)
35. Emery, A.E. Duchenne Muscular Dystrophy. Oxford University Press, 1993.
36. Bradley, D.M., Parsons, E.P., and Clarke, A.J. Experience with screening newborns for Duchenne muscular dystrophy in Wales. BMJ 1993, 306(6874): 357-60. (Pubitemid 23039392)
37. Drousiotou, A., Ioannou, P., Georgiou, T. et al. Neonatal screening for Duchenne muscular dystrophy: A novel semiquantitative application of the bioluminescence test for creatine kinase in a pilot national program in Cyprus. Genet Test 1998, 2(1): 55-60.
38. Scheuerbrandt, G., Lundin, A., Lovgren, T., Mortier, W. Screening for Duchenne muscular dystrophy: An improved screening test for creatine kinase and its application in an infant screening program. Muscle Nerve 1986, 9(1): 11-23. (Pubitemid 16076347)
39. Zellweger, H., Antonik, A. Newborn screening for Duchenne muscular dystrophy. Pediatrics 1975, 55(1): 30-4.
40. Edwards, R.J., Watts, D.C., Watts, R.L., Rodeck, C.H. Creatine kinase estimation in pure fetal blood samples for the prenatal diagnosis of Duchenne muscular dystrophy. Prenat Diagn 1984, 4(4): 267-77. (Pubitemid 14031295)
41. Emery, A.E. Muscle histology and creatine kinase levels in the foetus in Duchenne muscular dystrophy. Nature 1977, 266(5601): 472-3. (Pubitemid 8067233)
42. Ebashi, S., Tokyokura, Y., Momoi, H., Sugita, H. High creatine phosphokinase activity of sera of progressive muscular dystrophy. J Biochem (Tokyo) 1959, 46: 103-4.
43. Murphy, D.L., Mendell, J.R., Engel, W.K. Serotonin and platelet function in Duchenne muscular dystrophy. Arch Neurol 1973, 28(4): 239-42
44. Engel, W.K. [New theory on the pathogenesis of Duchenne's pseudohypertrophic muscular dystrophy]. Rev Neurol (Paris) 1971, 124(4): 291-8.
45. Burbach, J.A. Ultrastructure of cardiocyte degeneration and myocardial calcification in the dystrophic hamster. Am J Anat 1987, 179(3): 291-307. (Pubitemid 17106919)
46. Jerusalem, F., Engel, A.G., Gomez, M.R. Duchenne dystrophy. I. Morphometric study of the muscle microvasculature. Brain 1974, 97(1): 115-22.
47. Kobayashi, Y., Suzuki, H., Iinuma, K., Tada, K., Yamamoto, T.Y. Endothelial alterations of skeletal muscle capillaries in childhood myopathies. Tohoku J Exp Med 1983, 140(4): 381-9. (Pubitemid 14236647)
48. Miike, T., Sugino, S., Ohtani, Y., Taku, K., Yoshioka, K. Vascular endothelial cell injury and platelet embolism in Duchenne muscular dystrophy at the preclinical stage. J Neurol Sci 1987, 82(1-3): 67-80. (Pubitemid 18001989)
49. Musch, B.C., Papapetropoulos, T.A., McQueen, D.A., Hudgson, P., Weightman, D. A comparison of the structure of small blood vessels in normal, denervated and dystrophic human muscle. J Neurol Sci 1975, 26(2): 221-34.
50. Sugino, S., Miyatake, M., Ohtani, Y., Yoshioka, K., Miike, T., Uchino, M. Vascular alterations in Fukuyama type congenital muscular dystrophy. Brain Dev 1991, 13(2): 77-81.
51. Coral-Vazquez, R., Cohn, R.D., Moore, S.A. et al. Disruption of the sarcoglycan-sarcospan complex in vascular smooth muscle: A novel mechanism for cardiomyopathy and muscular dystrophy. Cell 1999, 98(4): 465-74. (Pubitemid 29402484)
52. Durbeej, M., Cohn, R.D., Hrstka, R.F. et al. Disruption of the beta-sarcoglycan gene reveals pathogenetic complexity of limb-girdle muscular dystrophy type 2E. Mol Cell 2000, 5(1): 141-51. (Pubitemid 30105443)
53. Loufrani, L., Dubroca, C., You, D., Li, Z., Levy, B., Paulin, D., Henrion, D. Absence of dystrophin in mice reduces NO-dependent vascular function and vascular density: Total recovery after a treatment with the aminoglycoside gentamicin. Arterioscler Thromb Vasc Biol 2004, 24(4): 671-6. (Pubitemid 38451602)
54. Hunter, E.G., Elbrink, J. Increased contractility in vascular smooth muscle of dystrophic hamsters. Can J Physiol Pharmacol 1983, 61(2): 182-5. (Pubitemid 13156572)
55. Conway, R.S., Factor, S.M., Sonnenblick, E.H., Baez, S. Microvascular reactivity of the myopathic Syrian hamster cremaster muscle. Cardiovasc Res 1987, 21(11): 796-803. (Pubitemid 17159886)
56. Miyatake, M., Miike, T., Zhao, J., Yoshioka, K., Uchino, M., Usuku, G. Possible systemic smooth muscle layer dysfunction due to a deficiency of dystrophin in Duchenne muscular dystrophy. J Neurol Sci 1989, 93(1): 11-7. (Pubitemid 19244004)
57. Noordeen, M.H., Haddad, F.S., Muntoni, F., Gobbi, P., Hollyer, J.S., Bentley, G. Blood loss in Duchenne muscular dystrophy: Vascular smooth muscle dysfunctio. J Pediatr Orthop B 1999, 8(3): 212-5. (Pubitemid 29296299)
58. Loufrani, L., Matrougui, K., Gorny, D., Duriez, M., Blanc, I., Levy, B.I., Henrion, D. Flow (shear stress)-induced endothelium-dependent dilation is altered in mice lacking the gene encoding for dystrophin. Circulation 2001, 103(6): 864-70. (Pubitemid 32163886)
59. Durbeej, M., Sawatzki, S.M., Barresi, R., Schmainda, K.M., Allamand, V., Michele, D.E., Campbell, K.P. Gene transfer establishes primacy of striated vs. smooth muscle sarcoglycan complex in limb-girdle muscular dystrophy. Proc Natl Acad Sci U S A 2003, 100(15): 8910-5. (Pubitemid 36899197)
60. Demos, J., Ecoiffier, J. [Circulatory disorders during muscular disease; arteriographic research]. Rev Franc Etudes Clin Biol 1957, 2(5): 489-94.
61. Emery, A.E., Schelling, J.L. Limb blood flow in patients and carriers of Duchenne muscular dystrophy. Acta Genet Stat Med 1965, 15(3): 337-44.
62. Bradley, W.G., O'Brien, M.D., Walder, D.N., Murchison, D., Johnson, M., Newell, D.J. Failure to confirm a vascular cause of muscular dystrophy. Arch Neurol 1975, 32(7): 466-73.
63. Paulson, O.B., Engel, A.G., Gomez, M.R. Muscle blood flow in Duchenne type muscular dystrophy, limb-girdle dystrophy, polymyositis, and in normal control. J Neurol Neurosurg Psychiatry 1974, 37(6): 685-90.
64. Corcondilas, A., Koroxenidis, G.T., Shepherd, J.T. Effect of a brief contraction of forearm muscles on forearm blood flow. J Appl Physiol 1964, 19: 142-6.
65. Mendell, J.R., Engel, W.K., Derrer, E.C. Duchenne muscular dystrophy: Functional ischemia reproduces its characteristic lesions. Science 1971, 172(988): 1143-5.
66. Ito, K., Kimura, S., Ozasa, S. et al. Smooth muscle-specific dystrophin expression improves aberrant vasoregulation in mdx mice. Hum Mol Genet 2006, 15(14): 2266-75. (Pubitemid 43985517)
67. Rando, T.A. Role of nitric oxide in the pathogenesis of muscular dystrophies: A "two hit" hypothesis of the cause of muscle necrosis. Microsc Res Tech 2001, 55(4): 223-35. (Pubitemid 33136322)
68. Knudson, A.G. Jr. Mutation and cancer: Statistical study of retinoblastoma. Proc Natl Acad Sci U S A 1971, 68(4): 820-3.
69. Nordling, C.O. A new theory on cancer-inducing mechanism. Br J Cancer 1953, 7(1): 68-72.
70. Ervasti, J.M., Campbell, K.P. Membrane organization of the dystrophin-glycoprotein complex. Cell 1991, 66(6): 1121-31. (Pubitemid 121001402)
71. Ervasti, J.M., Campbell, K.P. A role for the dystrophin-glycoprotein complex as a transmembrane linker between laminin and actin. J Cell Biol 1993, 122(4): 809-23. (Pubitemid 23241091)
72. Ozawa, E. Our trails and trials in the subsarcolemmal cytoskeleton network and muscular dystrophy researches in the dystrophin era. Proc Jpn Acad Ser 2010, 886: 798-821.
73. Tinsley, J.M., Blake, D.J., Zuellig, R.A., Davies, K.E. Increasing complexity of the dystrophin-associated protein complex. Proc Natl Acad Sci U S A 1994, 91(18): 8307-13. (Pubitemid 24273653)
74. Yoshida, M., Hama, H., Ishikawa-Sakurai, M. et al. Biochemical evidence for association of dystrobrevin with the sarcoglycan-sarcospan complex as a basis for understanding sarcoglycanopathy. Hum Mol Genet 2000, 9(7): 1033-40. (Pubitemid 30216008)
75. Brenman, J.E., Chao, D.S., Xia, H., Aldape, K., Bredt, D.S. Nitric oxide synthase complexed with dystrophin and absent from skeletal muscle sarcolemma in Duchenne muscular dystrophy. Cell 1995, 82(5): 743-52.
76. Sotgia, F., Lee, J.K., Das, K. et al. Nitric oxide synthase complexed with dystrophin and absent from skeletal muscle sarcolemma in Duchenne muscular dystrophy. J Biol Chem 2000, 275(48): 38048-58.
77. Madhavan, R., Jarrett, H.W. Calmodulin-activated phosphorylation of dystrophin. Biochemistry 1994, 33(19): 5797-804. (Pubitemid 24184583)
78. Prins, K.W., Humston, J.L., Mehta, A., Tate, V., Ralston, E., Ervasti, J.M. Dystrophin is a microtubule-associated protein. J Cell Biol 2009, 186(3): 363-9.
79. Crosbie, R.H., Barresi, R., Campbell, K.P. Loss of sarcolemma nNOS in sarcoglycan-deficient muscle. FASEB J 2002, 16(13): 1786-91. (Pubitemid 35340359)
80. Wehling, M., Spencer, M.J., Tidball, J.G. A nitric oxide synthase transgene ameliorates muscular dystrophy in mdx mice. J Cell Biol 2001, 155(1): 123-31. (Pubitemid 34286213)
81. Tidball, J.G., Wehling-Henricks, M. Expression of a NOS transgene in dystrophin-deficient muscle reduces muscle membrane damage without increasing the expression of membrane-associated cytoskeletal proteins. Mol Genet Metab 2004, 82(4): 312-20. (Pubitemid 39078711)
82. Toda, N., Okamura, T. Possible role of nitric oxide in transmitting information from vasodilator nerve to cerebroarterial muscle. Biochem Biophys Res Commun 1990, 170(1): 308-13. (Pubitemid 20249420)
83. Ayajiki, K., Hayashida, H., Tawa, M., Okamura, T., Toda, N. Characterization of nitrergic function in monkey penile erection in vivo and in vitro. Hypertens Res 2009, 32(8): 685-9.
84. Gordon, G.R., Howarth, C., Macvicar, B.A. Bidirectional control of arteriole diameter by astrocytes. Exp Physiol 2011, 96(4): 393-9.
85. Zehetgruber, M., Conforto, A., Bing, R.J. Vascular smooth muscle and nitric oxide. Life Sci 1993, 52(17): 1397-406.
86. Pradhan, R.K., Chakravarthy, V.S. Informational dynamics of vasomotion in microvascular networks: A review. Acta Physiol (Oxf) 2011, 201(2): 193-218.
87. Downey, J.M., Davis, A.M., Cohen, M.V. Signaling pathways in ischemic preconditioning. Heart Fail Rev 2007, 12(3-4): 181-8. (Pubitemid 350176691)
88. Costa, A.D., Pierre, S.V., Cohen, M.V., Downey, J.M., Garlid, K.D. (2008) cGMP signalling in pre- and post-conditioning: The role of mitochondria. Cardiovasc Res 2008, 77(2): 344-52. (Pubitemid 351197643)
89. Burley, D.S., Ferdinandy, P., Baxter, G.F. Cyclic GMP and protein kinase-G in myocardial ischaemia-reperfusion: Opportunities and obstacles for survival signaling. Br J Pharmacol 2007, 152(6): 855-69. (Pubitemid 350100488)
90. Wang, H., Kohr, M.J., Traynham, C.J., Ziolo, M.T. Phosphodiesterase 5 restricts NOS3/soluble guanylate cyclase signaling to L-type Ca2+ current in cardiac myocytes. J Mol Cell Cardiol 2009, 47(2): 304-14.
91. Gorbe, A., Giricz, Z., Szunyog, A., Csont, T., Burley, D.S., Baxter, G.F., Ferdinandy, P. Role of cGMP-PKG signaling in the protection of neonatal rat cardiac myocytes subjected to simulated ischemia/reoxygenation. Basic Res Cardiol 2010, 105(5): 643-50.
92. Zhang, Q., Scholz, P.M., Pilzak, A., Su, J., Weiss, H.R. Role of phospholamban in cyclic GMP mediated signaling in cardiac myocytes. Cell Physiol Biochem2007, 20(1-4): 157-66. (Pubitemid 46956821)
93. Zhang, Q., Scholz, P.M., He, Y., Tse, J., Weiss, H.R. Cyclic GMP signaling and regulation of SERCA activity during cardiac myocyte contraction. Cell Calcium 2005, 37(3): 259-66.
94. Das, A., Salloum, F.N., Xi, L., Rao, Y.J., Kukreja, R.C. ERK phosphorylation mediates sildenafil-induced myocardial protection against ischemia-reperfusion injury in mice. Am J Physiol Heart Circ Physiol 2009, 296(5): H1236-43.
95. Das, A., Xi, L., Kukreja, R.C. Protein kinase G-dependent cardioprotective mechanism of phosphodiesterase-5 inhibition involves phosphorylation of ERK and GSK3beta. J Biol Chem 2008, 283(43): 29572-85.
96. Costa, A.D., Garlid, K.D. Intramitochondrial signaling: Interactions among mitoKATP, PKCepsilon, ROS, and MPT. Am J Physiol Heart Circ Physiol 2008, 295(2): H874-82.
97. Johlfs, M.G., Fiscus, R.R. Protein kinase G type-Ialpha phosphorylates the apoptosis-regulating protein Bad at serine 155 and protects against apoptosis in N1E-115 cells. Neurochem Int 2010, 56(4): 546-53.
98. Fiedler, B., Feil, R., Hofmann, F. et al. cGMP-dependent protein kinase type I inhibits TAB1-p38 mitogen-activated protein kinase apoptosis signaling in cardiac myocytes. J Biol Chem 2006, 281(43): 32831-40. (Pubitemid 46036838)
99. Vidavalur, R., Penumathsa, S.V., Thirunavukkarasu, M., Zhan, L., Krueger, W., Maulik, N. Sildenafil augments early protective transcriptional changes after ischemia in mouse myocardium. Gene 2009, 430(1-2): 30-7.
100. Stephens, R.S., Rentsendorj, O., Servinsky, L.E., Moldobaeva, A., Damico, R., Pearse, D.B. cGMP increases antioxidant function and attenuates oxidant cell death in mouse lung microvascular endothelial cells by a protein kinase G-dependent mechanism. Am J Physiol Lung Cell Mol Physiol 2010, 299(3): L323-33.
101. Chiueh, C.C., Andoh, T., Chock, P.B. Roles of thioredoxin in nitric oxide-dependent preconditioning-induced tolerance against MPTP neurotoxin. Toxicol Appl Pharmacol 2005, 207(2, Suppl.): 96-102.
102. Koitabashi, N., Aiba, T., Hesketh, G.G. et al. Cyclic GMP/PKG-dependent inhibition of TRPC6 channel activity and expression negatively regulates cardiomyocyte NFAT activation Novel mechanism of cardiac stress modulation by PDE5 inhibition. J Mol Cell Cardiol 2010, 48(4): 713-24.
103. Sokolowska, M., Bednarski, M., Kwiecien, I., Filipek, B., Wlodek, L. Bioactivation of nitroglycerin to nitric oxide (NO) and S-nitrosothiols in the rat liver and evaluation of the coexisting hypotensive effect. Fundam Clin Pharmacol 2004, 18(4): 449-56. (Pubitemid 39215357)
104. Aoki, H., Inoue, M., Mizobe, T., Harada, M., Imai, H., Kobayashi, A. Platelet function is inhibited by nitric oxide liberation during nitroglycerin-induced hypotension anaesthesia. Br J Anaesth 1997, 79(4): 476-81. (Pubitemid 27423327)
105. Sugita, H., Fujimoto, M., Yasukawa, T. et al. Inducible nitric-oxide synthase and NO donor induce insulin receptor substrate-1 degradation in skeletal muscle cells. J Biol Chem 2005, 280(14): 14203-11. (Pubitemid 40517322)
106. Sugita, H., Kaneki, M., Tokunaga, E. et al. Inducible nitric oxide synthase plays a role in LPS-induced hyperglycemia and insulin resistance. Am J Physiol Endocrinol Metab 2002, 282(2): E386-94. (Pubitemid 34654809)
107. Yasukawa, T., Tokunaga, E., Ota, H., Sugita, H., Martyn, J.A., Kaneki, M. S-nitrosylation-dependent inactivation of Akt/protein kinase B in insulin resistance. J Biol Chem 2005, 280(9): 7511-8. (Pubitemid 40349643)
108. Pinsky, D.J., Aji, W., Szabolcs, M. et al. Nitric oxide triggers programmed cell death (apoptosis) of adult rat ventricular myocytes in culture. Am J Physiol 1999, 277(3, Pt. 2): H1189-99. (Pubitemid 29459634)
109. Brown, G.C. Mechanisms of inflammatory neurodegeneration: iNOS and NADPH oxidase. Biochem Soc Trans 2007, 35(Pt. 5): 1119-21. (Pubitemid 350206442)
110. Bateman, R.M., Sharpe, M.D., Goldman, D., Lidington, D., Ellis, C.G. Inhibiting nitric oxide overproduction during hypotensive sepsis increases local oxygen consumption in rat skeletal muscle. Crit Care Med 2008, 36(1): 225-31.
111. Kirkeboen, K.A., Strand, O.A. The role of nitric oxide in sepsis - An overview. Acta Anaesthesiol Scand 1999, 43(3): 275-88. (Pubitemid 29109473)
112. Carroll, W.D., Dhillon, R. Sildenafil as a treatment for pulmonary hypertension. Arch Dis Child 2003, 88(9): 827-8. (Pubitemid 37094245)
113. Leibovitch, L., Matok, I., Paret, G. Therapeutic applications of sildenafil citrate in the management of paediatric pulmonary hypertension. Drugs 2007, 67(1): 57-73. (Pubitemid 46105087)
114. Sung, B.J., Hwang, K.Y., Jeon, Y.H. et al. Structure of the catalytic domain of human phosphodiesterase 5 with bound drug molecules. Nature 2003, 425(6953): 98-102. (Pubitemid 37101725)
115. Reffelmann, T., Kloner, R.A. Cardiovascular effects of phosphodiesterase 5 inhibitors. Curr Pharm Des 2006, 12(27): 3485-94. (Pubitemid 44400485)
116. Adamo, C.M., Dai, D.F., Percival, J.M. et al. Sildenafil reverses cardiac dysfunction in the mdx mouse model of Duchenne muscular dystrophy. Proc Natl Acad Sci U S A 2010, 107(44): 19079-83.
117. Corbin, J.D., Francis, S.H. Molecular biology and pharmacology of PDE-5-inhibitor therapy for erectile dysfunction. J Androl 2003, 24(6, Suppl.): S38-41. (Pubitemid 37370525)
118. Grover, F.W. Oxtriphylline glyceryl guaiacolate elixir in pediatric asthma: With a theophylline review. Ann Allergy 1965, 23: 127-47.
119. Burdi, R., Rolland, J.F., Fraysse, B. et al. Multiple pathological events in exercised dystrophic mdx mice are targeted by pentoxifylline: Outcome of a large array of in vivo and ex vivo tests. J Appl Physiol 2009, 106(4): 1311-24.
120. Persson, I. [Etiology and a new treatment of progressive muscular dystrophy]. Nord Med 47(28): 965-7.
121. Thomson, W.H., Guest, K.E. A trial of therapy by nucleosides and nucleotides in muscular dystrophy. J Neurol Neurosurg Psychiatry 1963, 26: 111-22.
122. Stelgens, P. [The treatment of progressive muscular dystrophy (Erb) with adenosine triphosphate]. Dtsch Med Wochenschr 1957, 82(41): 1761-3.
123. Cosmos, E., Butler, J. Animal models of muscle diseases, Part III: Compilation of therapeutic trials for hereditary muscular dystrophy. Muscle Nerve 1980, 3(5): 427-35. (Pubitemid 11191521)
124. Cote, R.H. Characteristics of photoreceptor PDE (PDE6): Similarities and differences to PDE5. Int J Impot Res 2004, 16(Suppl. 1): S28-33. (Pubitemid 38993081)
125. Laties, A.M. Vision disorders and phosphodiesterase type 5 inhibitors: A review of the evidence to date. Drug Saf 2009, 32(1): 1-18.
126. Kostis, J.B., Jackson, G., Rosen, R. et al. Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference). Am J Cardiol 2005, 96(12B): 85M-93M. (Pubitemid 43017226)
127. Gargante, M.P., Vacante, M., Russo, C., Malaguarnera, M. Myopathy with concurrent tadalafil and simvastatin. Case Report Med 2009, 378287.
128. Gutierrez, C.A. Sildenafil-simvastatin interaction: Possible cause of rhabdomyolysis? Am Fam Physician 2001, 63(4): 636-7. (Pubitemid 32178689)
129. Farooq, M.U., Naravetla, B., Moore, P.W., Majid, A., Gupta, R., Kassab, M.Y. Role of sildenafil in neurological disorders. Clin Neuropharmacol 2008, 31(6): 353-62.
130. Vignos, P.J. Jr., Spencer, G.E. Jr., Archibald, K.C. Management of progressive muscular dystrophy in childhood. JAMA 1963, 184: 89-96.
131. Scott, O.M., Hyde, S.A., Goddard, C., Dubowitz, V. Quantitation of muscle function in children: A prospective study in Duchenne muscular dystrophy. Muscle Nerve1982, 5(4): 291-301. (Pubitemid 12070783)
132. Swinyard, C.A., Deaver, G.G., Greenspan, L. Gradients of functional ability of importance in rehabilitation of patients with progressive muscular and neuromuscular diseases. Arch Phys Med Rehabil 1957, 38(9): 574-9.
133. Brooke, M.H., Griggs, R.C., Mendell, J.R., Fenichel, G.M., Shumate, J.B. The natural history of Duchenne muscular dystrophy: A caveat for therapeutic trials. Trans Am Neurol Assoc 1981, 106: 195-9.
134. Coulton, G.R., Curtin, N.A., Morgan, J.E., Partridge, T.A. The mdx mouse skeletal muscle myopathy: II. Contractile properties. Neuropathol Appl Neurobiol 1988, 14(4): 299-314.
135. Sacco, P., Jones, D.A., Dick, J.R., Vrbova, G. Contractile properties and susceptibility to exercise-induced damage of normal and mdx mouse tibialis anterior muscle. Clin Sci (Lond) 1992, 82(2): 227-36.
136. Tanabe, Y., Esaki, K., Nomura, T. Skeletal muscle pathology in X chromosome-linked muscular dystrophy (mdx) mouse. Acta Neuropathol (Berl) 1986, 69(1-2): 91-5. (Pubitemid 16146255)
137. Valentine, B.A., Cooper, B.J., Cummings, J.F., De Lahunta, A. Canine X-linked muscular dystrophy: morphologic lesions. J Neurol Sci 1990, 97(1): 1-23. (Pubitemid 20190521)
138. Mastaglia, F.L., Papadimitriou, J.M., Kakulas, B.A. Regeneration of muscle in Duchenne muscular dystrophy: An electron microscope study. J Neurol Sci 1970, 11(5): 425-44.
139. Watkins, S.C., Cullen, M.J. A qualitative and quantitative study of the ultrastructure of regenerating muscle fibres in Duchenne muscular dystrophy and polymyositis. J Neurol Sci 1987, 82(1-3): 181-92. (Pubitemid 18001999)
140. Quinlan, J.G., Cambier, D., Lyden, S. et al. Regeneration-blocked mdx muscle: In vivo model for testing treatments. Muscle Nerve 1997, 20(8): 1016-23. (Pubitemid 27306514)
141. Wakeford, S., Watt, D.J., Partridge, T.A. X-irradiation improves mdx mouse muscle as a model of myofiber loss in DMD. Muscle Nerve 1991, 14(1): 42-50.
142. Balagopal, P., Olney, R., Darmaun, D., Mougey, E., Dokler, M., Sieck, G., Hammond, D. Oxandrolone enhances skeletal muscle myosin synthesis and alters global gene expression profile in Duchenne muscular dystrophy. Am J Physiol Endocrinol Metab 2006, 290(3): E530-9. (Pubitemid 43671701)
143. Nagasue, N., Yukaya, H., Ogawa, Y., Kohno, H., Nakamura, T. Human liver regeneration after major hepatic resection. A study of normal liver and livers with chronic hepatitis and cirrhosis. Ann Surg 1987, 206(1): 30-9. (Pubitemid 17101849)
144. Kaita, K.D., Pettigrew, N., Minuk, G.Y. Hepatic regeneration in humans with various liver disease as assessed by Ki-67 staining of formalin-fixed paraffin-embedded liver tissue. Liver 1997, 17(1): 13-6. (Pubitemid 27092776)
145. Suzuki, H., Ohta, Y., Takino, T. Effects of glycyrrhizin on biochemical tests in patients with chronic hepatitis. Igakuno Ayumi 1977, 102: 562-78.
146. Kumada, H. Long-term treatment of chronic hepatitis C with glycyrrhizin [stronger neo-minophagen C (SNMC)] for preventing liver cirrhosis and hepatocellular carcinoma. Oncology 2002, 62(Suppl. 1): 94-100. (Pubitemid 34702027)
147. Yamanaka, M., Ofuji, M., Obata, H. Double-blind study on the efficacy of ursodeoxycholate on chronic hepatitis [Nijunmouken-hou niyoru urusodeokikishikoorusan no mansei kan-en ni taisuru chiryoukouka no kentou]. Diagnosis Treatment (Shindan to Chiryo). 1976, 64-2150-7
148. Morandi, L., Bernasconi, P., Gebbia, M., Mora, M., Crosti, F., Mantegazza, R., Cornelio, F. Lack of mRNA and dystrophin expression in DMD patients three months after myoblast transfer. Neuromuscul Disord 1995, 5(4): 291-5.
149. Banker, B.Q., Hirst, N.S., Chester, C.S., Fok, R.Y. Histometric and electron cytochemical study of muscle in the dystrophic mouse. Ann N Y Acad Sci 1979, 317: 115-31.
150. Hausmanowa-Petrusewicz, I., Ryniewicz, B. Electromyographic findings in the so-called non-progressive myopathies. J Neurol 1976, 211(3): 241-51.
151. O'Doherty, D.S., Schellinger, D., Raptopoulos, V. Computed tomographic patterns of pseudohypertrophic muscular dystrophy: Preliminary results. J Comput Assist Tomogr 1977, 1(4): 482-6. (Pubitemid 8228114)
152. Heckmatt, J.Z., Dubowitz, V., Leeman, S. Detection of pathological change in dystrophic muscle with B-scan ultrasound imaging. Lancet 1980, 1(8183): 1389-90.
153. Misra, L.K., Kasturi, S.R., Kundu, S.K. Evaluation of muscle degeneration in inherited muscular dystrophy by nuclear magnetic resonance techniques. Magn Reson Imaging 1982, 1(2): 75-9. (Pubitemid 13014488)
154. Marden, F.A., Connolly, A.M., Siegel, M.J., Rubin, D.A. Compositional analysis of muscle in boys with Duchenne muscular dystrophy using MR imaging. Skeletal Radiol 2005, 34(3): 140-8. (Pubitemid 40305454)
155. Cady, E.B., Gardener, J.E., Edwards, R.H. Ultrasonic tissue characterisation of skeletal muscle. Eur J Clin Invest 1983, 13(6): 469-73. (Pubitemid 14248746)
156. Pillen, S., Tak, R.O., Zwarts, M.J. et al. Skeletal muscle ultrasound: Correlation between fibrous tissue and echo intensity. Ultrasound Med Biol 2009, 35(3): 443-6.
157. Ichida, F., Tsuji, T., Omata, M. et al. New Inuyama classification; new criteria for histological assessment of chronic hepatitis. International Hepatology Communications 1996, 6(2): 112-9. (Pubitemid 27059904)
158. Knodell, R.G., Ishak, K.G., Black, W.C. et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981, 1(5): 431-5. (Pubitemid 12218164)
159. Desmet, V.J., Gerber, M., Hoofnagle, J.H., Manns, M., Scheuer, P.J. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994, 19(6): 1513-20. (Pubitemid 24166476)
160. Chao, D.S., Gorospe, J.R., Brenman, J.E. et al. Selective loss of sarcolemmal nitric oxide synthase in Becker muscular dystrophy. J Exp Med 1996, 184(2): 609-18. (Pubitemid 26324114)
161. Grady, R.M., Grange, R.W., Lau, K.S., Maimone, M.M., Nichol, M.C., Stull, J.T., Sanes, J.R. Role for alpha-dystrobrevin in the pathogenesis of dystrophin-dependent muscular dystrophies. Nat Cell Biol 1999, 1(4): 215-20. (Pubitemid 129500940)
162. Howman, E.V., Sullivan, N., Poon, E.P., Britton, J.E., Hilton-Jones, D., Davies, K.E. Syncoilin accumulation in two patients with desmin-related myopathy. Neuromuscul Disord 2003, 13(1): 42-8. (Pubitemid 35430138)
163. Minetti, C., Bado, M., Broda, P. et al. Impairment of caveolae formation and T-system disorganization in human muscular dystrophy with caveolin-3 deficiency. Am J Pathol 2002, 160(1): 265-70. (Pubitemid 34052287)
164. Garcia-Cardena, G., Martasek, P., Masters, B.S. et al. Dissecting the interaction between nitric oxide synthase (NOS) and caveolin. Functional significance of the nos caveolin binding domain in vivo. J Biol Chem 1997, 272(41): 25437-40. (Pubitemid 27438846)
165. Tsai, A.G., Arfors, K.E., Intaglietta, M. Spatial distribution of red blood cells in individual skeletal muscle capillaries during extreme hemodilution. Int J Microcirc Clin Exp 1991, 10(4): 317-34.
166. Brooke, M.H., Griggs, R.C., Mendell, J.R., Fenichel, G.M., Shumate, J.B., Pellegrino, R.J. Clinical trial in Duchenne dystrophy. I. The design of the protocol. Muscle Nerve 1981, 4(3): 186-97. (Pubitemid 11098499)
167. Steffensen, B., Hyde, S., Lyager, S., Mattsson, E. Validity of the EK scale: A functional assessment of non-ambulatory individuals with Duchenne muscular dystrophy or spinal muscular atrophy. Physiother Res Int 2001, 6(3): 119-34.
168. Inoue, M., Mori, K., Hayabuchi, Y., Tatara, K., Kagami, S. Autonomic function in patients with Duchenne muscular dystrophy. Pediatr Int 2009, 51(1): 33-40.
169. Gresser, U., Gleiter, C.H. Erectile dysfunction: Comparison of efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil and tadalafil - Review of the literature. Eur J Med Res 2002, 7(10): 435-46.
170. Lugnier, C. Cyclic nucleotide phosphodiesterase (PDE) superfamily: A new target for the development of specific therapeutic agents. Pharmacol Ther 2006, 109(3): 366-98. (Pubitemid 43132818)